ReviewGastro hep advances2025
Comparison Between Adalimumab and Infliximab in Perianal Crohn's Disease: A Systematic Review and Meta-Analysis.
Review in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn's Disease: Current Evidence and Future Perspectives.Journal of clinical medicine · 2026Review
- Tissue penetration of anti-tumour necrosis factor therapy in perianal fistulising Crohn's disease: a proof-of-concept study.European journal of gastroenterology & hepatology · 2026Article
- Perianal Crohn's Disease in Inflammatory Bowel Disease: Diagnosis, Assessment and Treatment.Life (Basel, Switzerland) · 2026Review
- Optimizing Drug Positioning in IBD: Clinical Predictors, Biomarkers, and Practical Approaches to Personalized Therapy.Biomedicines · 2026Review
- Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Anti-tumor necrosis factor therapy has been a mainstay of medical management of perianal Crohn's disease (CD). This systematic review and meta-analysis aimed to compare the efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of perianal fistulizing CD. Methods: We searched PubMed, Embase, and Web of Science databases for studies that compared the efficacy of ADA with IFX for treatment of patients with perianal fistulizing CD. Single-arm studies were excluded. The primary outcomes were perianal CD healing evaluated clinically or radiologically. Results: Six observational studies with a total of 590 patients with perianal CD (216 received ADA and 374 received IFX) were included. Overall, perianal CD healing was comparable between ADA and IFX (risk ratio (RR) 0.90, 95% confidence interval (CI) 0.76-1.06, Conclusion: In this systematic review and meta-analysis, ADA was not inferior to IFX in effectiveness for the treatment of perianal CD. Head-to-head prospective and randomized controlled studies comparing ADA and IFX are necessary to validate the findings of this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.